Another group treating Burkitt lymphoma cells with the HSP90 inhibitor, PU176, also reported reduced tumor cell proliferation; however, they suggested the PI3K/AKT/mTOR pathway (but not MYC) as the main mechanism of action [15]. This evidence concerns the gene MTOR and Burkitt lymphoma.